Source: C. R. Bard Youtube Channel

C. R. Bard posted a video "BD WavelinQ EndoAVF: James and Brandy's Story (short version)" on YOUTUBE

See Video »
C. R. Bard's Competitors | C. R. Bard's News | C. R. Bard's Financials

March 27, 2023

MarketScreener

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

(marketscreener.com) Positive high-level results from the NEURO-TTRansform Phase III trial in patient... See more »

March 27, 2023

Korea Biomedical Review

Bayer vows to become a top oncology drugmaker

Bayer has vowed to become one of the world's top 10 pharmaceutical companies in the field of cancer.B... See more »

March 27, 2023

O'Dwyer's PR News

FGS Global Adds Medtronic, ExxonMobil Alum

Rob Clark, who headed communications at Medtronic and ExxonMobil in a 25-year career, has joined FGS ... See more »
C. R. Bard's News
March 27, 2023MarketScreener

UK stocks start the week higher as banks, AstraZeneca climb

(marketscreener.com) UK equities surged on Monday, as bank stocks rebounded on hopes that the turmoil... See more »
C. R. Bard's News
March 27, 2023FinanzNachrichten

AstraZeneca Reports Positive High-level Results From Phase 3 Study Of Eplontersen

LONDON (dpa-AFX) - AstraZeneca plc (AZN.L) Monday said its investigational drug eplontersen showed su... See more »
C. R. Bard's News
March 27, 2023Fox Business

Bayer plans to shift focus away from women's health drug research

Bayer has announced plans to shift its efforts away from women's health to focus on diseases, cardiov... See more »
C. R. Bard's News
March 25, 2023Biospectrum Asia

Bayer allocates resources to grow oncology and cardiology biz in US

New R&D strategy and operating model sharpening innovation focus and strengthening early development ... See more »

March 27, 2023

MarketScreener

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

(marketscreener.com) Positive high-level results from the NEURO-TTRansform Phase III trial in patient... See more »

March 27, 2023

Korea Biomedical Review

Bayer vows to become a top oncology drugmaker

Bayer has vowed to become one of the world's top 10 pharmaceutical companies in the field of cancer.B... See more »

March 27, 2023

O'Dwyer's PR News

FGS Global Adds Medtronic, ExxonMobil Alum

Rob Clark, who headed communications at Medtronic and ExxonMobil in a 25-year career, has joined FGS ... See more »
C. R. Bard's News
March 27, 2023MarketScreener

UK stocks start the week higher as banks, AstraZeneca climb

(marketscreener.com) UK equities surged on Monday, as bank stocks rebounded on hopes that the turmoil... See more »
C. R. Bard's News
March 27, 2023FinanzNachrichten

AstraZeneca Reports Positive High-level Results From Phase 3 Study Of Eplontersen

LONDON (dpa-AFX) - AstraZeneca plc (AZN.L) Monday said its investigational drug eplontersen showed su... See more »
C. R. Bard's News
March 27, 2023Fox Business

Bayer plans to shift focus away from women's health drug research

Bayer has announced plans to shift its efforts away from women's health to focus on diseases, cardiov... See more »
C. R. Bard's News
March 25, 2023Biospectrum Asia

Bayer allocates resources to grow oncology and cardiology biz in US

New R&D strategy and operating model sharpening innovation focus and strengthening early development ... See more »
Stay up-to-date with the latest news on C. R. Bard
Est. Annual Revenue
$1.0-5.0B
Agree?
Est. Employees
10-50K
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Read more
Stay up-to-date with the latest news on C. R. Bard